نتائج البحث

1

Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies

المؤلفون: Sapna Pradyuman Patel, David S. Hong, Vivek Subbiah, Amanda Johnston, Siqing Fu, John S. Bomalaski, Sarina Anne Piha-Paul, Shuyang Yao, Ahmed Kaseb, Aung Naing, Nai Shi, Filip Janku, Apostolia Maria Tsimberidou, Shannon N. Westin, John Stewart

المصدر: Br J Cancer

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d35421e6155a20aeb943eeead2c5143Test
https://doi.org/10.1038/s41416-020-01230-8Test

2

Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers

المؤلفون: Xin Wei Wang, Ole Larsen, Julia S. Johansen, Colm J O'Rourke, Dan Høgdall, Jesper B. Andersen, Morten Mau-Sørensen, Mogens Karsboel Boisen, Astrid Z. Johansen, Dorte Linnemann, Hien Dang, Douglas V. N. P. Oliveira, Valentina M. Factor, Lars Henrik Jensen, Christian Dehlendorff, Mie Grunnet

المصدر: Høgdall, D, O'Rourke, C J, Dehlendorff, C, Larsen, O F, Jensen, L H, Johansen, A Z, Dang, H, Factor, V M, Grunnet, M, Mau-Sørensen, M, Oliveira, D V N P, Linnemann, D, Boisen, M K, Wang, X W, Johansen, J S & Andersen, J B 2020, ' Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers ', Clinical Cancer Research, vol. 26, no. 21, pp. 5655-5667 . https://doi.org/10.1158/1078-0432.CCR-19-2700Test
Clin Cancer Res

مصطلحات موضوعية: Adult, Male, musculoskeletal diseases, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Locally advanced, Inflammation, Deoxycytidine, Article, Disease-Free Survival, Mice, 03 medical and health sciences, 0302 clinical medicine, In vivo, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, medicine, Animals, Humans, Antigens, Tumor-Associated, Carbohydrate, Prognostic biomarker, Chitinase-3-Like Protein 1, Aged, Cell Proliferation, Aged, 80 and over, Interleukin-6, Proportional hazards model, business.industry, Palliative Care, Middle Aged, Prognosis, Receptors, Interleukin-6, Gemcitabine, Progression-Free Survival, Clinical trial, Biliary Tract Neoplasms, 030104 developmental biology, Biliary tract, 030220 oncology & carcinogenesis, Female, medicine.symptom, business, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db1883a3389ee7e27bcc0a6669a1e847Test
https://doi.org/10.1158/1078-0432.ccr-19-2700Test

3

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 10
Clin Cancer Res

مصطلحات موضوعية: Male, 0301 basic medicine, Cancer Research, Programmed Cell Death 1 Receptor, Phases of clinical research, Neuroendocrine tumors, Gastroenterology, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Clinical endpoint, CTLA-4 Antigen, Prospective Studies, Prospective cohort study, Cancer, Aged, 80 and over, Middle Aged, Prognosis, Survival Rate, Neuroendocrine Tumors, Nivolumab, Oncology, 6.1 Pharmaceuticals, 030220 oncology & carcinogenesis, Female, medicine.drug, Adult, medicine.medical_specialty, Clinical Trials and Supportive Activities, Oncology and Carcinogenesis, Ipilimumab, Article, Pancreatic Cancer, 03 medical and health sciences, Rare Diseases, Clinical Research, Internal medicine, medicine, Humans, Oncology & Carcinogenesis, Intermediate Grade, Survival rate, Aged, business.industry, Neurosciences, Evaluation of treatments and therapeutic interventions, medicine.disease, 030104 developmental biology, Digestive Diseases, business, Follow-Up Studies

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af0a5916b106134919751addb6c490a4Test
https://doi.org/10.1158/1078-0432.ccr-19-3356Test

4

A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients

المؤلفون: Charles LeVea, Grace K. Dy, Wei Tan, Laura Pitzonka, Patrick McKay Boland, Renuka Iyer, Alex A. Adjei, Hao Xie, Robert M. Straubinger, Sarah A Schihl, William E. Brady, Krystin Mantione, Amy Whitworth, Wen Wee Ma, Gerald J. Fetterly, John Wilton

المصدر: American Journal of Clinical Oncology. 42:184-189

مصطلحات موضوعية: Adult, Male, Cancer Research, Maximum Tolerated Dose, Quinolones, Deoxycytidine, Article, Capecitabine, 03 medical and health sciences, 0302 clinical medicine, Pharmacokinetics, Neoplasms, Pancreatic cancer, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Tissue Distribution, Receptor, Fibroblast Growth Factor, Type 1, 030212 general & internal medicine, Survival rate, Aged, Aged, 80 and over, business.industry, Middle Aged, Prognosis, medicine.disease, Gemcitabine, Pancreatic Neoplasms, Survival Rate, Clinical trial, Receptors, Vascular Endothelial Growth Factor, Oncology, Fibroblast growth factor receptor, 030220 oncology & carcinogenesis, Maximum tolerated dose, Cancer research, Benzimidazoles, Female, business, Follow-Up Studies, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cc3babf7e001739ec14179f912c6003Test
https://doi.org/10.1097/coc.0000000000000492Test

5

Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas

المصدر: Clin Cancer Res

مصطلحات موضوعية: 0301 basic medicine, Neuroblastoma RAS viral oncogene homolog, MAPK/ERK pathway, Male, Cancer Research, Skin Neoplasms, Time Factors, Programmed Cell Death 1 Receptor, Kaplan-Meier Estimate, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Prospective Studies, Child, Immune Checkpoint Inhibitors, Melanoma, Aged, 80 and over, Kinase, Middle Aged, Prognosis, Nivolumab, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Gain of Function Mutation, Female, Mitogen-Activated Protein Kinases, medicine.drug, Adult, Adolescent, MAP Kinase Signaling System, Ipilimumab, Article, 03 medical and health sciences, Young Adult, medicine, Humans, Aged, Retrospective Studies, Proportional hazards model, business.industry, medicine.disease, Immune checkpoint, 030104 developmental biology, Drug Resistance, Neoplasm, Cancer research, Neoplasms, Unknown Primary, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c49254bc0ee296ae1962986b33235d9Test
https://pubmed.ncbi.nlm.nih.gov/33509808Test

6

Prognostic and predictive significance of nuclear HIF1α expression in locally advanced HNSCC patients treated with chemoradiation with or without nimotuzumab

المؤلفون: Vijay Patil, Asawari Patil, Neha Mittal, Amit Joshi, Sadhana Kannan, Swapnil Rane, Manoj B. Mahimkar, Poonam Gera, Vanita Noronha, Manish Kumar Pandey, Tanuja A. Samant, Kumar Prabhash, Usha Patel

المصدر: British Journal of Cancer

مصطلحات موضوعية: Oncology, Male, Cancer Research, Radiation-Sensitizing Agents, Gene Dosage, Kaplan-Meier Estimate, Alphapapillomavirus, law.invention, Tumour biomarkers, 0302 clinical medicine, Antineoplastic Agents, Immunological, Randomized controlled trial, law, Young adult, Head and neck cancer, Hazard ratio, Chemoradiotherapy, Middle Aged, Prognosis, Progression-Free Survival, ErbB Receptors, Head and Neck Neoplasms, 030220 oncology & carcinogenesis, Cohort, Female, medicine.drug, Adult, medicine.medical_specialty, Antibodies, Monoclonal, Humanized, Predictive markers, Article, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Biomarkers, Tumor, Nimotuzumab, Humans, Progression-free survival, Aged, Proportional Hazards Models, Cell Nucleus, business.industry, Proportional hazards model, Squamous Cell Carcinoma of Head and Neck, Hypoxia-Inducible Factor 1, alpha Subunit, Clinical trial, Cisplatin, business, Negative Results

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9431f247069663c647d62345367e24c9Test
https://pubmed.ncbi.nlm.nih.gov/32939054Test

7

A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies

المؤلفون: Philippe Armand, John M. Timmerman, Alexander M. Lesokhin, Ivan Borrello, Mihaela Popa McKiver, Lili Zhu, Stephen M. Ansell, Martin Gutierrez

المصدر: Leukemia

مصطلحات موضوعية: Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Lymphoma, Programmed Cell Death 1 Receptor, Salvage therapy, Ipilimumab, Article, Young Adult, Alkaloids, Receptors, KIR, Internal medicine, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, medicine, Biomarkers, Tumor, Humans, CTLA-4 Antigen, Survival rate, Multiple myeloma, Aged, Aged, 80 and over, Salvage Therapy, business.industry, Lymphoma, Non-Hodgkin, Hematology, Middle Aged, medicine.disease, Prognosis, Hodgkin Disease, Blockade, Survival Rate, Nivolumab, Tolerability, Drug Resistance, Neoplasm, Female, Neoplasm Recurrence, Local, business, Multiple Myeloma, medicine.drug, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dea15b8905ec241a20d6013080a1e39aTest
https://pubmed.ncbi.nlm.nih.gov/32601377Test

8

Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells

المؤلفون: Dhifaf Sarhan, Angela Panoskaltsis-Mortari, Jeffrey S. Miller, Linda J. Burns, Bruce R. Blazar, Veronika Bachanova, Sarah Cooley, Todd E. DeFor, Julie M. Curtsinger, Daniel J. Weisdorf

المصدر: Cancer Immunology, Immunotherapy. 67:483-494

مصطلحات موضوعية: Adult, Male, Cancer Research, Adolescent, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Immunology, Graft vs Host Disease, Hematopoietic stem cell transplantation, Immunotherapy, Adoptive, Article, Donor Selection, Cell therapy, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Immune system, Biomarkers, Tumor, medicine, Humans, Transplantation, Homologous, Immunology and Allergy, Prospective Studies, Receptors, Immunologic, Child, Aged, Donor selection, business.industry, Lymphoma, Non-Hodgkin, Myeloid-Derived Suppressor Cells, Remission Induction, Hematopoietic Stem Cell Transplantation, Middle Aged, Prognosis, medicine.disease, Lymphoma, Killer Cells, Natural, Cytokine release syndrome, Oncology, 030220 oncology & carcinogenesis, Myeloid-derived Suppressor Cell, Female, Rituximab, business, Immunosuppressive Agents, Follow-Up Studies, 030215 immunology, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa457a0287c32ccd371c951124d66970Test
https://doi.org/10.1007/s00262-017-2100Test-1

9

Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer

المصدر: Elander, N O, Augthton, K, Ghaneh, P, Neoptolemos, J P, Palmer, DH, Cox, T F, Campbell, F, Costello, E, Halloran, CM, Mackey, JR, Scarfe, A G, Valle, J, McDonald, AC, Carter, R, Tebbutt, NC, Goldstein, D, Shannon, J, Dervenis, C, Glimelius, B, Deakin, M, Charnley, RM, Anthoney, A, Lerch, MM, Mayerle, J, Olah, A, Buchler, MW & Greenhalf, W 2018, ' Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. ', British Journal of Cancer, vol. 118, pp. 947-954 . https://doi.org/10.1038/s41416-018-0004-2Test
British Journal of Cancer

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_treatment, pancreatic cancer, Leucovorin, Dihydropyrimidine dehydrogenase (DPD), Deoxycytidine, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, randomized trial, Medicine, 5-fluorouracil, Randomized Controlled Trials as Topic, Aged, 80 and over, Manchester Cancer Research Centre, Hazard ratio, gemcitabine, Middle Aged, Prognosis, Immunohistochemistry, human equilibrative nucleoside transporter 1 (hENT1), 030220 oncology & carcinogenesis, Female, Fluorouracil, Adjuvant, Carcinoma, Pancreatic Ductal, medicine.drug, Adult, medicine.medical_specialty, Article, Equilibrative Nucleoside Transporter 1, 03 medical and health sciences, Folinic acid, adjuvant, Internal medicine, Pancreatic cancer, Biomarkers, Tumor, Dihydropyrimidine dehydrogenase, Humans, predictive, Dihydrouracil Dehydrogenase (NADP), Aged, Cancer och onkologi, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, medicine.disease, Survival Analysis, Gemcitabine, Confidence interval, Pancreatic Neoplasms, 030104 developmental biology, Tissue Array Analysis, Cancer and Oncology, business, prognostic

وصف الملف: application/vnd.openxmlformats-officedocument.wordprocessingml.document; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab29624a2b543c89b77e832264ee43a8Test
https://doi.org/10.1038/s41416-018-0004-2Test

10

Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients

المساهمون: Department of Dermatology [Tubingen, Germany], University Medical Center [Tubingen, Germany], Department of Internal Medicine II [Tübingen, Germany], University Medical Center [Tübingen, Germany], Immunité et cancer (U932), Université Paris Descartes - Paris 5 (UPD5)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), The Netherlands Cancer Institute [Amsterdam, The Netherlands], Memorial Sloane Kettering Cancer Center [New York], Weill Medical College of Cornell University [New York], Istituto Nazionale Tumori Fondazione Pascale [Naples, Italy], Department of Dermatology [Essen, Germany], University Hospital [Essen, Germany]-West German Cancer Center [Essen, Germany]-University Duisburg-Essen [Germany], German Cancer Consortium [Heidelberg] (DKTK), Division of Medical Oncology and Immunotherapy [Siena, Italy], University Hospital of Siena, Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), School of Science and Technology [Nottingham, U.K.], Nottingham Trent University, Division of Cancer Studies [London, UK], King‘s College London, Parts of this study were funded by Bristol-Myers Squibb (Munich, Germany) to B Weide. Parts of this study were funded by the EU Seventh Framework Program ‘PRIAT’ (Profiling Responders In Antibody Therapies) grant agreement no 305309 to C Garbe. Parts of this study were funded by Deutsche Forschungsgemeinschaft DFG PA 361-22/1 to G. Pawelec., European Project: 305309,EC:FP7:HEALTH,FP7-HEALTH-2012-INNOVATION-1,PRIAT(2012), Bernardo, Elizabeth, Profiling Responders In Antibody Therapies - PRIAT - - EC:FP7:HEALTH2012-11-01 - 2014-10-31 - 305309 - VALID, Immunité et cancer ( U932 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut Curie-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Memorial Sloan Kettering Cancer Center [New York, NY, USA], Weill Cornell Medical College [New York, NY, USA], German Cancer Consortium - DKTK [Heidelberg, Germany], Centre de Recherche en Cancérologie / Nantes - Angers ( CRCNA ), CHU Angers-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hôpital Laennec-Centre National de la Recherche Scientifique ( CNRS ) -Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes ( CHU Nantes ), Nottingham Trent University [U.K.], European Project : 305309,EC:FP7:HEALTH,FP7-HEALTH-2012-INNOVATION-1,PRIAT ( 2012 ), Universität Duisburg-Essen = University of Duisburg-Essen [Essen]-University Hospital [Essen, Germany]-West German Cancer Center [Essen, Germany]

المصدر: European Journal of Cancer
European Journal of Cancer, 2017, 73, pp.61-70. ⟨10.1016/j.ejca.2016.12.011⟩
European Journal of Cancer, Elsevier, 2017, 73, pp.61-70. 〈10.1016/j.ejca.2016.12.011〉
European Journal of Cancer, Elsevier, 2017, 73, pp.61-70. ⟨10.1016/j.ejca.2016.12.011⟩

مصطلحات موضوعية: CD4-Positive T-Lymphocytes, Male, 0301 basic medicine, Oncology, Cancer Research, Skin Neoplasms, Programmed Cell Death 1 Receptor, Medizin, Kaplan-Meier Estimate, CD8-Positive T-Lymphocytes, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Biomarker, Effector memory cells, Ipilimumab, Melanoma, Prognosis, medicine.diagnostic_test, Effector, Antibodies, Monoclonal, Middle Aged, Flow Cytometry, Peripheral, 030220 oncology & carcinogenesis, Biomarker (medicine), Female, medicine.drug, Adult, medicine.medical_specialty, Antineoplastic Agents, [SDV.CAN]Life Sciences [q-bio]/Cancer, Peripheral blood mononuclear cell, Article, Flow cytometry, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, Antigens, Neoplasm, Internal medicine, Biomarkers, Tumor, medicine, Humans, Aged, business.industry, medicine.disease, 030104 developmental biology, Immunology, business, Immunologic Memory, CD8

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88a6982f18635313131b596d20ee2f8dTest
https://doi.org/10.1016/j.ejca.2016.12.011Test

تنقيح النتائج